Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [07/08/2025 07:20 PDT] sector Stocks Expected To Be Up After Top Correlated Stocks Fire Buy Signals.
• [06/26/2025 07:19 PDT] FENC Expected to Trade Up After Bullish Patterns Develop
• [06/09/2025 07:20 PDT] sector Stocks Expected To Be Up After Top Correlated Stocks Fire Buy Signals.
• [06/09/2025 07:18 PDT] FENC Expected to Trade Up After Bullish Patterns Develop
• [06/06/2025 15:34 PDT] Fennec Pharmaceuticals Inc. (NASDAQ:FENC), Up By 100% ($7.41) After BUYINS.NET SqueezeTrigger Report Released on Monday, May 19th 2025 at a Price of $7.41.
• [05/21/2025 07:27 PDT] FENC Expected to Trade Up After Bullish Patterns Develop
• [05/19/2025 15:33 PDT] FENC SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [05/13/2025 07:12 PDT] sector Stocks Expected To Be Down After Top Correlated Stocks Fire Sell Signals.